OpportunityAnalyzer: Hyperparathyroidism - Opportunity Analysis and Forecasts to 2025
Hyperparathyroidism (HPT) is a common endocrinal disorder characterized by excessive plasma levels of parathyroid hormone (PTH) stemming from overactivity of the parathyroid glands. The parathyroid glands, of which there are four, regulate physiological calcium homeostasis through a negative feedback mechanism involving PTH secretion. HPT is classified into either primary, secondary, or tertiary, and it is important to differentiate between the three as their underlying aetiology, pathology, and treatment differ.
Sales of hyperparathyroidism (HPT) therapeutics is estimated to be approximately $6.69B in 2015 across the seven major markets covered in this report (7MM): the US, the five major European markets (5EU: France, Germany, Italy, Spain, and UK), and Japan. In the 2015 base year, 92% of market share was attributed to secondary HPT (SHPT) therapy sales ($6.16B), whereas primary HPT (PHPT) and tertiary HPT (THPT) held just 4.5% ($307M) and 3.5% ($225M) of the market, respectively.
The most notable trend in corporate strategy in the hyperparathyroidism space was the attempt to develop drugs without the adverse effects seen with the available drug classes. This led to the introduction of cornerstone therapies: Sanofi/Genzyme’s first non-metal based phosphate binders, Renvela/Renagel (sevelamer hydrochloride/carbonate), and AbbVie’s first selective vitamin D receptor agonist (VDRA), Zemplar (paricalcitol), both of which did not cause the associated hypercalcemia seen with the previous standard of care (SOC). Corporate strategy at present follows a similar trend, being particularly gauged towards improving compliance with existing drug classes by enhancing their safety, tolerability, and/or efficacy profiles.
By 2025, it is expected that the HPT market will grow at a strong Compound Annual Growth Rate (CAGR) of 1.8%, reaching sales of $8.04B by the end of the forecast period. This is mainly attributed to growth in the SHPT space, which is forecast to reflect a CAGR of 2.2%, reaching $7.68B in sales by 2025 (96% of market share). In general, the US will contribute the most to the HPT market growth, as it is predicted to grow at a CAGR of 2.4%, from $3.97B in 2015 to $5.04B in 2025.
Major drivers of HPT market growth over the forecast period are the -
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook